BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
By Dr. Matthew Watson
SANTA MONICA, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, February 20, at 7 p.m. local time in 73M homes across the United States. The RedChip Money Report® also airs on Bloomberg International in Europe in 100M homes at 6 pm local time on Sundays.
See original here:
BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
Related Post
- Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 - January 14th, 2025
- Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - January 14th, 2025
- Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - January 14th, 2025
- Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - January 14th, 2025
- ProMIS Neurosciences Issues Letter to Shareholders - January 14th, 2025
- BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - January 14th, 2025
- OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer - January 14th, 2025
- Correction: GUERBET : Financial agenda for 2025 - January 14th, 2025
- Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without... - January 14th, 2025
- Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - January 14th, 2025
- Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - January 14th, 2025
- FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s... - January 14th, 2025
- Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - January 14th, 2025
- HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - January 14th, 2025
- Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- Idorsia publishes an invitation to a bondholder meeting - January 14th, 2025
- Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease - January 14th, 2025
- Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy... - January 14th, 2025
- Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 5th, 2025
- ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 5th, 2025
- SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® - January 5th, 2025
- Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - January 5th, 2025
- Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - January 5th, 2025
- Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - January 5th, 2025
- Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc. - January 5th, 2025
- VALNEVA Declaration of shares and voting rights: December 31, 2024 - January 5th, 2025
- Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Procaps Group Receives Additional Delinquency Letter - January 5th, 2025
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 5th, 2025
- BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - January 5th, 2025
- Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week - January 5th, 2025
- Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 5th, 2025
- BriaCell Announces Proposed Effective Date of Share Consolidation - January 5th, 2025
- PharmaTher Announces Grant of Stock Options - January 5th, 2025
- Oculis Publishes Notification of Major Changes in Voting Rights - January 5th, 2025
- Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 27th, 2024
- Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - December 27th, 2024
- Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - December 27th, 2024
- Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis - December 27th, 2024
- Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million - December 27th, 2024
- Abivax Announces a Change to the Composition of its Board of Directors - December 27th, 2024
- Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial - December 27th, 2024
- Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - December 27th, 2024
- Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - December 27th, 2024
- Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. - December 27th, 2024
- SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation - December 27th, 2024
- Optinose Announces 1-for-15 Reverse Stock Split - December 27th, 2024
- Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - December 27th, 2024
- Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing... - December 27th, 2024
- Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in... - December 27th, 2024
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - December 27th, 2024
- Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering - December 27th, 2024
- argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating... - December 27th, 2024
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally - December 18th, 2024
- Vaccinex Announces Receipt of Delisting Notification from Nasdaq - December 18th, 2024
- Adia Nutrition Unveils Exclusive Artwork by Renowned Performance Artist Rock Demarco at First Clinic - December 18th, 2024
- NYMOX Announces Trading Resumed and New Listing on OTCQB Market - December 18th, 2024
- Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy - December 18th, 2024
- AB Science provides a summary of the webcast held on December 16, 2024 - December 18th, 2024
- Ultimovacs ASA – Mandatory notification of trade - December 18th, 2024
- Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare... - December 18th, 2024
- Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA - December 18th, 2024
- Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
- Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18,... - December 18th, 2024
- Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - December 18th, 2024
- Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - December 18th, 2024
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic... - December 18th, 2024
- Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
- NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - December 18th, 2024
- AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - December 18th, 2024
- Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - December 18th, 2024
- NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology - December 18th, 2024
- Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution - December 18th, 2024
Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research